Cel Sci Corporation (CVM)

[drkazmd65]

IMO - if NICE does complete a review of Multikine and they say it belongs in the Great Britain SOC for head and neck cancer, then what the FDA choses to do is just a bonus in a lot of ways. The GB medical system - despite Brexit - still has close ties to what the rest of the EU does. And since H&N cancer is reportedly more abundant in Europe than in the US, that market is enough to drive share prices up to at least at the $25 level.

All I know is that we are likely in for an interesting, and positive, 2024 and beyond with CVM. I have been here in at least a small way since about 2009-10, but didn't really start adding much until after the Phase III trial results were revealed.